Latest news with #VerveTherapeutics
Yahoo
02-06-2025
- Business
- Yahoo
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 65,000 shares of the company's common stock and an aggregate of 22,000 restricted stock units (RSUs). The options have an exercise price of $4.45 per share, which is equal to the closing price of the company's common stock on the date of grant. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to each such employee's continued service with the company on each such vesting date. The RSUs will vest in equal annual installments on the first three anniversaries of July 1, 2025, subject to each such employee's continued service with the company on each such vesting date. About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company's lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: LDL-C, triglycerides, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit Investor ContactJen RobinsonVerve Therapeutics, Media ContactAshlea Kosikowski1ABashlea@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Print
26-05-2025
- Health
- The Print
Experimental drug promising to bring down bad cholesterol by up to 69% completes early stage trial
The potential breakthrough medicine developed by US-based biotechnology firm Verve Therapeutics is a novel, in vivo (delivered directly into the body), base editing medicine that permanently turns off the PCSK9 gene (a protein that plays a role in regulating cholesterol levels in the blood) in the liver, thereby reducing disease-causing bad cholesterol. High levels of low-density lipoprotein cholesterol (LDL-C), commonly referred to as bad cholesterol, are among the leading causes of heart attacks and strokes, the two top reasons as per the World Health Organisation (WHO) for mortality worldwide as well as India. New Delhi: Would you believe it if someone tells you that the risk of you suffering a heart attack or a stroke could be dramatically reduced by a single injection once in your lifetime? That is exactly the promise that results from an early stage trial of an experimental drug in the US has shown, bringing down bad cholesterol by up to 69 percent after just one shot. The results from its stage 1b clinical trial show that intravenous infusion of the drug, named VERVE 102 currently, led to a mean LDL reduction of 53 percent among patients receiving the highest dose, with the maximum individual reduction reaching 69 percent, the company said in a statement. The drug suppressed PCSK9 levels by an average of 60 percent at the highest dose. Among the 14 participants across three dose levels, the drug was well-tolerated, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities observed, the company said. Specialists, however, insist results from a large group of patients would be crucial. The drug has triggered a buzz in the global pharmaceutical industry and is now set to enter a larger trial across five countries to test the efficacy and safety. 'These initial results from the early trial of the drug are very interesting and promise, for the first time, a lifetime treatment of a condition that is main risk factor for several serious cardiovascular events,' Dr Ambuj Roy, a senior cardiologist at the All India Institute of Medical Sciences (AIIMS), New Delhi, told ThePrint. The clinician-researcher also underlined that data from the drug's trial on a larger group of people would be pivotal before hopes are raised. The company has maintained that the initial data are promising with respect to both safety and efficacy, and suggest the potential for a new era of cardiovascular disease treatment where a single dose 'might lead to lifelong control of LDL-C'. Verve has tied up with pharma giant Eli Lilly and Company to co-commercialise the drug following successful trials and regulatory approvals. WHO defines raised total cholesterol or dyslipidemia—which includes LDL-C—over 5 millimole or 190 mg/dL and it is estimated that nearly 39 percent of adults worldwide suffer from dyslipidemia. A large survey carried out by the Indian Council of Medical Research (ICMR) and the Madras Diabetes Research Foundation, published in The Lancet in 2023, had shown 81.2 percent Indians have dyslipidemia and 20.9 percent—or 18.5 crore—have high levels of bad cholesterol. Also Read: India gets 1st guidelines for managing lipid levels, the biggest risk factor for heart attack, stroke What sets the drug apart As of now, statins are the most commonly used pharmacotherapies to lower cholesterol levels and work by inhibiting an enzyme called HMG-CoA reductase that is involved in the synthesis of cholesterol in the liver. But experts say that while statins and various lipid-lowering medications have greatly diminished cardiovascular risks in many patients, there is an urgent requirement for improved, more specific drugs to manage cholesterol. Such need, explained Dr Amit Bhushan Sharma, the director and unit head of cardiology at Paras Health in Gurugram, is particularly evident in patients with statin intolerance, genetic dyslipidemias such as familial hypercholesterolemia (or high cholesterol), and in those who fail to reach target lipid levels despite receiving optimal treatment. New therapies like PCSK9 inhibitors, inclisiran—a small interfering RNA (siRNA) therapy that offers sustained LDL-C reduction with just two doses a year launched in India last year—and bempedoic acid have created new possibilities, but they remain underused because of cost and access challenges, experts say. Amid this, there is an increasing interest in RNA-based and gene-editing treatments that may offer lasting cholesterol management with reduced side-effects. 'Improved cholesterol-lowering medications could help reduce the residual cardiovascular risk in high-risk populations, prevent recurrent cardiac events, and potentially offer better safety profiles for patients with comorbidities,' Sharma added. The cardiologist also said that a more personalised approach to cholesterol management—driven by advanced pharmacological options—could be the next big step in preventive cardiology. Verve has said the drug trial has been aimed at evaluating its result in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), two populations that require deep and durable reductions of bad cholesterol levels in the blood. (Edited by Ajeet Tiwari) Also Read: A new AI tool can predict if you'll have a heart attack 10 years later, shows 1st global trial
Yahoo
29-04-2025
- Business
- Yahoo
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street
Equity markets have been volatile this year due to macroeconomic and geopolitical factors. Many of the world's largest corporations haven't escaped the sell-off, and it's hard to predict what's next. Even so, Wall Street has high hopes for some companies. Take Verve Therapeutics (NASDAQ: VERV), a small-cap, clinical-stage biotech. Based on the drugmaker's average price target of $24.43 (according to Yahoo! Finance), the stock could soar by 321% in the next 12 months. That isn't unheard of in the exciting biotech industry, but before rushing to buy Verve Therapeutics' shares, here's what investors need to know about the company. Clinical-stage biotech stocks can experience significant value increases due to promising clinical or regulatory news. If Verve Therapeutics has any chance of soaring by more than 300% in the next year, the company will have to impress the market with its leading candidate, VERVE-102. This product is nowhere close to approval, but can it make enough progress to match the Street's estimates? Notably, Verve Therapeutics recently announced positive results from a Phase 1b clinical trial for VERVE-102 as a potential treatment for heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » HeFH is a genetic disease that causes elevated levels of LDL cholesterol (LDL-C) -- also known as "bad" cholesterol -- which, in high concentration, can lead to severe cardiovascular issues. During the study, a single injection of VERVE-102, an in vivo gene editing therapy, led to a mean LDL-C reduction of 53% in patients. The medicine also showed a reasonable safety profile. These results look promising, especially when considering VERVE-102's potential target market. Verve Therapeutics estimates that there are approximately three million patients in the U.S. and the European Union with HeFH, and 31 million globally. While treatment courses exist, they typically focus on lowering LDL-C levels. VERVE-102, with just one infusion, could address the problem at its source -- a one-time curative option might be a game changer in this area. That said, it will still be a while before VERVE-102 is approved. Verve Therapeutics plans to start phase 2 in the second half of the year. Further, it could still encounter clinical and regulatory setbacks. For all those reasons (and more), Verve Therapeutics' recent clinical success "only" led to a 24% share price increase in one day. Verve Therapeutics is unlikely to see its share price double -- let alone quadruple -- in the next year. There won't be much more significant progress for VERVE-102 in this period, while its other pipeline candidates, which are still in early-stage studies, are unlikely to have a bigger impact on its stock performance than its leading program. Still, that doesn't mean the stock isn't a good investment. Should investors consider adding shares of the gene editing specialist to their portfolios? Like most clinical-stage biotech companies, Verve Therapeutics is far too risky for most investors and isn't worth the trouble, at least not yet. True, it has the backing of a pharmaceutical giant, Eli Lilly, with which it is partnering to develop VERVE-102. That makes it less likely that Verve Therapeutics will run into funding issues -- something that can severely damage a small drugmaker's prospects. It's also true that Verve Therapeutics' approach could set a new standard of care for HeFH and some related cardiovascular diseases. Even so, it will take at least a couple of years before VERVE-102 starts Phase 3 studies, assuming everything goes as expected for the company. If Verve Therapeutics encounters significant headwinds with its leading program, investors could be left with (almost) worthless shares. So, while the stock has considerable upside potential, provided everything goes as planned, there is also ample downside risk. Risk-averse investors should watch this one unfold from the sidelines for now, despite Wall Street's lofty expectations. Before you buy stock in Verve Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Verve Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $594,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $680,390!* Now, it's worth noting Stock Advisor's total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 28, 2025 Prosper Junior Bakiny has positions in Eli Lilly. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street was originally published by The Motley Fool Sign in to access your portfolio
Globe and Mail
15-04-2025
- Business
- Globe and Mail
Why Verve Therapeutics Is Skyrocketing Today
Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Several analysts have now raised their price targets on the stock, and investors are buying up shares in response. Verve Therapeutics stock sees a swell of bullish coverage In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy. The firm's analysts said that results for VERVE-102 had come in better than expected in terms of both safety and efficacy. Guggenheim also published new coverage on Verve this morning -- maintaining a buy rating on the stock and raising its one-year price target from $18 per share to $24 per share. The firm's analysts cheered on the results for the Heart-2 Phase 1b trial and now sees a 75% chance that the treatment will be successfully marketed -- up from its previous estimate of 60%. Canaccord was even more bullish. The firm reiterated a buy rating on the stock and increased its one-year price target from $32 per share to $39 per share, saying that safety and efficacy results for the treatment in the trial had knocked it out of the park. What's next for Verve Therapeutics? Verve is scheduled to share more information about VERVE-102 at a medical conference this quarter, including trial data from the treatment at a higher dosage level. With the treatment potentially delivering best-in-class results, Verve stock could have room to run above current levels. Should you invest $1,000 in Verve Therapeutics right now? Before you buy stock in Verve Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Verve Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $502,231!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $678,552!* Now, it's worth noting Stock Advisor 's total average return is800% — a market-crushing outperformance compared to156%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of April 14, 2025
Yahoo
15-04-2025
- Business
- Yahoo
Why Verve Therapeutics Is Skyrocketing Today
Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Several analysts have now raised their price targets on the stock, and investors are buying up shares in response. In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy. The firm's analysts said that results for VERVE-102 had come in better than expected in terms of both safety and efficacy. Guggenheim also published new coverage on Verve this morning -- maintaining a buy rating on the stock and raising its one-year price target from $18 per share to $24 per share. The firm's analysts cheered on the results for the Heart-2 Phase 1b trial and now sees a 75% chance that the treatment will be successfully marketed -- up from its previous estimate of 60%. Canaccord was even more bullish. The firm reiterated a buy rating on the stock and increased its one-year price target from $32 per share to $39 per share, saying that safety and efficacy results for the treatment in the trial had knocked it out of the park. Verve is scheduled to share more information about VERVE-102 at a medical conference this quarter, including trial data from the treatment at a higher dosage level. With the treatment potentially delivering best-in-class results, Verve stock could have room to run above current levels. Before you buy stock in Verve Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Verve Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $502,231!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $678,552!* Now, it's worth noting Stock Advisor's total average return is 800% — a market-crushing outperformance compared to 156% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 14, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Verve Therapeutics Is Skyrocketing Today was originally published by The Motley Fool
